Novel 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-*c*]pyridines. Potent angiotensin II receptor antagonists with high affinity for both the AT₁ and AT₂ subtypes*

WWKR Mederski^{1**}, D Dorsch¹, M Osswald¹, H Schwartz¹, N Beier², M Christadler², KO Minck², P Schelling², CJ Schmitges²

¹Preclinical Pharmaceutical Research, Medicinal Chemistry, Merck KGaA, 64271 Darmstadt; ²Cardiovascular Pharmacology, Merck KGaA, 64271 Darmstadt, Germany

(Received 7 October 1996; accepted 12 February 1997)

Summary — The synthesis and pharmacological activity of balanced high affinity non-peptide angiotensin II antagonists of the AT_1 and AT_2 subtype receptors have been presented. A series of previously prepared AT_1 selective 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-*c*]-pyridines were modified at four different positions in order to increase the AT_2 binding affinity by maintaining the nanomolar activity for the AT_1 receptor. The targeted AT_2/AT_1 IC₅₀ binding ratio of ~ 1 was achieved with a number of compounds possessing a small alkyl chain at C-2, different acetamide groups at N-5 and a 3-fluoro and 2'-carboxamidosulfonyl substituent at the biphenylmethyl moiety. These modifications led to analogue **12s**, which exhibited an AT_2/AT_1 ratio of 0.74, a subnanomolar AT_1 antagonistic potency (0.18 nM) and a high metabolic stability in rat and monkey liver microsomes in vitro. After oral administration of 3 mg/kg to cynomolgus monkeys, EMD 90423 (potassium salt of **12s**) demonstrated good efficacy and a long duration of action as an anti-hypertensive agent.

4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine / biphenylsulfonamide / angiotensin II receptor antagonist / AT₁/AT₂ receptor subtype / antihypertensive activity

Introduction

The vasoactive hormone angiotensin II (ang II) produced by the renin–angiotensin system (RAS) is a potent regulator of blood pressure homeostasis, fluid volume and electrolyte balance in mammals [1]. The clinical success achieved by angiotensin converting enzyme (ACE) inhibitors in the treatment of hypertension and congestive heart failure has made the RAS a major focus for the discovery of novel antihypertensive agents [2]. However, ACE also has kininase activity, and this lack of specifity has been implicated in the occasional side effects of ACE inhibitors such as dry cough and angioedema [3]. With the development of ang II receptor antagonists, a more specific attempt to inhibit the activity of the RAS has become the main pharmacological approach.

There are at least two distinct ang II receptor subtypes, designated as AT_1 and AT_2 [4]. Losartan 1

(scheme 1), the most advanced non-peptide ang II receptor antagonist, mediates its effects by blocking the ang II AT₁ receptor subtype [5]. The AT₁ receptor is G-protein coupled [6] and mediates most of the known physiological effects of ang II, including the maintenance of blood pressure [7]. In recent years, a number of highly active non-peptide AT₁ selective ang II antagonists have been described [8]. In our group, 1,2-dihydropyridin-2-ones [9, 10], (6-oxo-3-pyrazinyl)-benzimidazoles [11], 4,5-dihydro-3*H*-imidazo[4,5-*c*]-pyridin-4-ones [12], 7-ethyl-1,2-dihydroquinolin-2-ones [13] and 1,2,3,4-tetrahydropyrimidin-2,4-diones [14] have been studied as selective AT₁ antagonists.

With the discovery of the non-peptide ligand PD 123,177 **3** (scheme 1) the AT_2 receptor subtype has been identified in various tissues [15]. The AT_2 receptor also has a 7-transmembrane domain and is linked to phosphotyrosine phosphatase activity [16, 17]. The physiological role of this receptor has not yet been clearly defined, but recent studies have indicated that it may play a role in wound healing, cardiac remodelling and cerebral blood flow [7]. However, it has been shown that in the presence of a AT_1 selective antago-

^{*}Dedicated to Professor Dr Dr hc Ekkehard Winterfeldt, Hannover, on the occasion of his 65th birthday.

^{**}Correspondence and reprints. e-mail: mederski@merck.de



Scheme 1. Selected structures of angiotensin II receptor antagonists.

nist (eg, losartan) the plasma concentration of ang II increases considerably [18]. To avoid an unopposed stimulation of the AT_2 receptor by the increased ang II plasma concentration, the development of balanced AT_1/AT_2 receptor antagonists seemed to be justified due to safety considerations, even though a clear physiological response to AT_2 receptor stimulation has not been shown yet.

Thus, it seemed reasonable to develop compounds which would bind to both ang II subtypes. High affinity non-peptide AT₁/AT₂-balanced ang II ligands were first realized by 6-quinazolinones such as L-159,689 4 (scheme 1) [19]. More recently, several other compounds with high affinity for both the AT_1 and AT_2 receptors have been described [20-24]. We previously reported the identification of the highly potent AT₁ receptor antagonist EMD 66684 2 (scheme 1) [12]. During further studies of the structure-activity relationship (SAR) of 2, we discovered structural modifications that enhanced the binding affinity of the imidazo[4,5-c]pyridine class of antagonists to the AT₂ receptor. Replacement of the dimethylacetamide in 2 by the phenylacetic acid isopropylester moiety led to a compound with a pronounced affinity for this subtype (AT₁ = 6.5 nM, AT₂ = 32.0 nM; AT₂/AT₁ = 5) [25]. Our next goal was to identify compounds with low nanomolar IC₅₀ values for both the AT₁ and the AT₂ receptors and to achieve an AT₂/AT₁ IC₅₀ ratio of ~ 1.

In this article, we report the synthesis and SAR studies of imidazo[4,5-c]pyridin-2-one derivatives as highly potent AT₁ receptor antagonists with AT₂/AT₁ binding ratios close to unity.

Chemistry

Two synthetic routes were used to generate the new compounds 11, 12 and 13 shown in tables II–IV. The *N*-tert-butylsulfonamide intermediates 8, 9 and 10 prepared during the course of this work are listed in table I.

For the majority of these compounds, the key intermediates 8, 9 and 10 were prepared in two steps by alkylation of the parent 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-c]pyridines **5** [12] with the appropriate 4'-(bromomethyl)-*N*-tert-butyl-2-biphenylsulfonamide [26] or the corresponding 3-fluoro analogue [22] in the presence of potassium carbonate in dimethylformamide (scheme 2). This gave rise to a mixture of the desired compounds 6 and the bisalkylated products 7, which were easily separated by silica gel chromatography. The regiochemistry of the alkylation could be verified by observation of nuclear Overhauser effects on compounds 6. Deprotonation of the N-5 hydrogen in 6 with potassium *tert*-butoxide in dimethylformamide and reaction of the resulting anion with the appropriate electrophiles exclusively gave the N-alkylated derivatives 8, 9 or 10. Removal of the tert-butyl group via trifluoroacetic acid led to the free sulfonamides, which were treated with acid chlorides or chloroformates in pyridine in the presence of 4-dimethylaminopyridine to give the targeted sulfonylamides or sulfonylcarbamates 11, 12 or 13 respectively.

In order to circumvent the bisalkylation problem in scheme 2, we sought a pathway which could be regiospecific and unequivocal. Several sulfonylamides and sulfonylcarbamates 13 were prepared by the alternate route shown in scheme 3. This general method is well illustrated by the preparation of compound 13i. N-(4-Amino-2-chloro-3-pyridyl)butyramide 12, which is readily available from 3,4-diamino-2-chloropyridine [12], was converted in six steps to the desired sulfonylamide 13i. Alkylation of 12 with 4-bromo-2-fluorobenzylbromide provided a mixture of 13 and 14 in a regiospecific manner. Compounds 13 and 14 can be identified after separation by chromatography on silica gel, but heating this crude reaction mixture with hydrochloric acid directly afforded the required com-

$R \xrightarrow{N-R^2} O N-R^2$							
Compound	R	R ¹	R^2	Empirical formula ^a	Mp (°C)		
8a	Bu	CH ₂ Ph	Н	$C_{34}H_{38}N_4O_3S.0.5 H_2O$	134–135		
8b	Bu	CH ₂ CONPh ₂	Н	$C_{41}H_{43}N_5O_4S$	178–179		
8c	Bu	CH ₂ CONMe ₂	Н	$C_{31}H_{39}N_5O_4S$	90-91		
9a	Bu	CH ₂ CONMe ₂	F	$C_{31}H_{38}FN_5O_4S$	177-178		
10a	Pr	CH ₂ CONMe ₂	F	$C_{30}H_{36}FN_5O_4S$	82-83		
10b	Et	CH ₂ CONMe ₂	F	$C_{29}H_{34}FN_5O_4S \cdot 1.5 H_2O$	81-82		
9b	Bu	CH ₂ Ph	F	$C_{34}H_{37}FN_4O_3S$	103-104		
9c	Bu	CH ₂ COPh	F	$C_{35}H_{38}N_4O_4S \cdot 1.7 H_2O$	127-128		
9d	Bu	CH ₂ CH ₂ COPh	F	$C_{36}H_{39}FN_4O_4S-0.5H_2O$	70-71		
9e	Bu	CH ₂ COMe	F	$C_{30}H_{35}FN_4O_4S$ •1.0 H_2O	103–104		
9f	Bu	CH ₂ COt-Bu	F	$C_{33}H_{41}FN_4O_4S \cdot 1.0 H_2O$	87–88		
9g	Bu	CH ₂ COn-Bu	F	$C_{33}H_{41}FN_4O_4S$	57–58		
9h	Bu	CH ₂ COOEt	F	$C_{31}H_{37}FN_4O_5S$	72–73		
9i	Bu	CH ₂ CONHCH ₂ <i>i</i> -Pr	F	$C_{33}H_{42}FN_5O_4S$	131–132		
9k	Bu	CH ₂ CONH <i>n</i> -Pr	F	$C_{32}H_{40}FN_5O_4S$	168–169		
9m	Bu	CH ₂ CONHt-Bu	F	$C_{33}H_{42}FN_5O_4S-1.0$ H ₂ O	83-84		
9n	Bu	CH ₂ CONHCH ₂ Ph	F	$C_{36}H_{40}FN_5O_4S$	178–179		
90	Bu	CH ₂ COpip ^b	F	$\mathbf{C}_{34}\mathbf{H}_{42}\mathbf{FN}_5\mathbf{O}_4\mathbf{S}$	145–146		
9p	Bu	CH ₂ CONEt ₂	F	$C_{33}H_{42}FN_5O_4S$	83–84		
9q	Bu	CH ₂ CONH ₂	F	$C_{29}H_{34}FN_5O_4S$	94–95		
10c	Pr	CH ₂ CONH <i>n</i> -Pn	F	$C_{33}H_{42}FN_5O_4S$	144–145		
10d	Pr	CH ₂ CONH <i>n</i> -Bu	F	$C_{32}H_{40}FN_5O_4S$	99-100		
10e	Pr	CH ₂ CONH <i>n</i> -Pr	F	$C_{31}H_{38}FN_5O_4S$	172-173		
10f	Pr	CH ₂ CONH(CH ₂) ₂ <i>i</i> -Pr	F	$C_{33}H_{42}FN_5O_4S$	167–168		
10g	Pr	CH ₂ CONH(CH ₂) ₃ <i>i</i> -Pr	F	$C_{34}H_{44}FN_5O_4S \cdot 1.0 H_2O$	105-106		
10h	Pr	CH ₂ CONH <i>t</i> -Bu	F	$C_{32}H_{40}FN_5O_4S.0.5 H_2O$	74–75		
10i	Pr	CH ₂ COpip ^b	F	$C_{33}H_{40}FN_5O_4S$	154–155		

Table I. Physical and chemical data of intermediates 8, 9 and 10.

^aAnalyses for C, H, N were correct to within ± 0.4% of theoretical values unless otherwise stated; ^bpip: piperidinyl.



Scheme 2. Reagents: a) K_2CO_3 , 4'-(bromomethyl)-*N*-tert-butyl-2-biphenylsulfonamide or 4'-(bromomethyl)-3'-fluoro-*N*-tert-butyl-2-biphenylsulfonamide, DMF, rt; b) KOt-Bu, R²-[Br,Cl], DMF, rt; c) TFA, rt; d) pyridine, DMAP, R³-COCl, rt.

pound 15. Following this, 15 was reacted with 1-chloroacetylpiperidine in dimethylformamide in the presence of potassium *tert*-butoxide to give the alkylated derivative 16. This product was then crosscoupled with [2-(N-tert-buty[sulfamoy])pheny]]boronic acid [22] using [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) [27] to obtain the key intermediate 10i (table I). The bidentate ligand of the palladium catalyst speeded up the reductive elimination in the catalytic cycle and was essential for a high turnover in this reaction step. The use of tetrakis-(triphenylphosphine)palladium (0) predominantly led to debromination of compound 16. The tert-butyl group in 10i was subsequently removed by treatment with trifluoroacetic acid, and the free sulfonamide was acylated with 3-phenylpropionyl chloride in pyridine to give the final compound 13i.

Results and discussion

All compounds in tables II–IV were evaluated in vitro for their binding affinities for the AT_1 subtype ang II receptor (IC₅₀), determined in rat adrenal cortical membranes, and for their binding affinities for ang II AT_2 receptors (IC₅₀) in a rat adrenal medulla preparation using [¹²⁵I] ang II as the radioligand. With selected acylsulfonamides in table VI, compound-mediated AT_1 antagonism of angiotensin II in vitro was determined in isolated rabbit thoracic aorta. Losartan **1**, EMD 66684 **2**, PD 123,177 **3** and L-159,689 **4** were used as reference standards in these assays.

To finally obtain balanced AT_1/AT_2 receptor antagonists, our intention was to construct AT_2 affinity by structural modifications of our AT_1 selective imidazo-[4,5-*c*]pyridin-2-ones such as EMD 66684 **2**.



Scheme 3. Reagents: a) KOt-Bu, 4-bromo-2-fluorobenzylbromide, NMP, rt; b) HCl, 105 °C; c) KOt-Bu, 1-chloroacetylpiperidine, DMF, rt; d) Na₂CO₃, Pd (dppf) Cl₂, [2-(Ntert-butylsulfamoyl)phenyl]boronic acid, MeOCH2CH2OMe, 84 °C; e) TFA, rt; f) pyridine, DMAP, PhCH₂CH₂COCl, rt.

In a previous paper we described that the introduction of an isopropyl phenylacetate in the N-5 position of compound 2 resulted in the discovery of our first compound with an improved affinity for the AT₂ receptor $(IC_{50}(AT_2) = 32.0 \text{ nM})$ [25]. However, the ester functionality was required for AT₂ activity since the corresponding acid showed markedly less AT₂ affinity, and the pronounced hydrolysis of the isopropylester in vivo hindered further advancement of these compounds [25].

Table II. Physical, chemical and biological data of target compounds 11.

We began our SAR studies by examining the effects of various modifications of the biphenyltetrazole moiety (table II). Initially we replaced the tetrazole unit by other bioisosters such as oxadiazoles or acylsulfonamides. The butoxycarbonylsulfonamide 11c, the first compound prepared in the sulfonamide series, gave a 30-fold improvement in AT_2 affinity over that obtained for 2 while retaining nanomolar binding affinity for the AT₁ receptor. Maintaining the butoxycarbonyl group and introducing more lipophilic (benzyl) or bulky (diphenylacetamide) substituents at the N-5 position delivered two compounds, 11a and 11b, which were only moderately active concerning binding affinity for the AT_1 receptor.

Next, a number of dimethylacetamide analogues of **11c** were prepared to optimize the sulfonamide substituent (\mathbb{R}^2 in table II). In this series, the phenylethylcarboxamidosulfonyl derivative 11e tended to be somewhat more potent at the AT_2 receptor than the other acylsulfonamides 11c, 11d, 11f and 11g.

In the course of that study, it became clear that the sulfonamide groups in these compounds were nearly optimized for AT₂ binding. Any significant additional enhancement regarding this affinity would need to be derived from changes made elsewhere in the molecule. When DuPont Merck scientists discovered that biphenyl 'ortho' substitution could increase the AT₂ affinity [28], we combined this 'ortho' substitution with the phenylethylcarboxamidosulfonyl acid isoster in **11e**. Introducing a 3-fluoro group in the biphenylmethyl moiety in **11e**, we were pleased to find that the biological activity was largely enhanced in compound 12a (table III). The 3-fluoro analogue 12a displayed a 22-fold improvement in AT_2 potency relative to the

Cmpd	R	R^{l}	R^2	Empirical formula ^a	Mp (°C)	AT_{l}^{b}	AT_2^{b}	Ratio AT_2/AT_1
11a	Bu	CH ₂ Ph	OBu	C ₃₅ H ₃₈ N ₄ O ₅ S•2.0 H ₂ O	118-119	34.0	135.0	4.0
11b	Bu	CH ₂ CONPh ₂	OBu	$C_{42}H_{43}N_5O_6S$	214-215	40.0	580.0	14.5
11c	Bu	CH ₂ CONMe ₂	OBu	$C_{32}H_{39}N_5O_6S$	91–92	4.4	345.0	78.4
11d	Bu	CH ₂ CONMe ₂	Ph	$C_{34}H_{35}N_5O_5S \cdot 0.5 H_2O$	224-225	2.9	1500.0	517.2
11e	Bu	CH ₂ CONMe ₂	$(CH_2)_2Ph$	$C_{36}H_{39}N_5O_5S$	195–196	4.7	210.0	44.7
11f	Bu	CH ₂ CONMe ₂	CH ₂ <i>i</i> -Pr	$C_{32}H_{39}N_5O_5S.0.5 H_2O$	212-213	4.2	1300.0	309.5
11g	Bu	CH ₂ CONMe ₂	CH ₂ t-Bu	$C_{33}H_{41}N_5O_5S$	149–150	10.0	4300.0	430.0

^aAnalyses for C, H, N were correct to within $\pm 0.4\%$ of theoretical values unless otherwise stated; ^bIC₅₀ values in nM. AT₁ receptor affinity was determined using rat adrenal cortical microsomes; AT₂ receptor affinities were determined using rat adrenal medulla microsomes (see *Experimental protocols*). In both cases [¹²⁵I] ang II was used as radioligand.

			R´ \				
Cmpd	R	R ¹	Empirical formula ^a	<i>Mp</i> (° <i>C</i>)	AT_i^{b}	AT ₂ ^b	Ratio AT ₂ /AT ₁
12a	Bu	CH ₂ CONMe ₂	C ₃₆ H ₃₈ FN ₅ O ₅ S•1.5 H ₂ O	201-202	3.1	9.3	3.0
13a	Pr	CH ₂ CONMe ₂	$C_{35}H_{36}FN_5O_5S \cdot 1.0 H_2O$	202-203	2.7	6.5	2.4
13b	Et	CH ₂ CONMe ₂	$C_{33}H_{32}FN_5O_5S$	195–196	3.8	18.0	4.7
12b	Bu	CH_2Ph	$C_{39}H_{37}FN_4O_4S$	121-122	35.0	16.5	0.5
12c	Bu	CH ₂ COPh	$C_{40}H_{37}FN_4O_5S$	144-145	30.0	24.0	0.8
12d	Bu	CH ₂ CH ₂ COPh	$C_{41}H_{39}FN_4O_5S$	67–68	39.0	26.0	0.7
12e	Bu	CH ₂ COMe	C ₃₅ H ₃₅ FN ₄ O ₅ S•1.0 H ₂ O	Oil	87.0	46.0	0.5
12f	Bu	CH ₂ COt-Bu	C ₃₈ H ₄₁ FN ₄ O ₅ S•1.7 H ₂ O	126-127	17.0	32.0	1.9
12g	Bu	CH ₂ COn-Bu	$C_{38}H_{41}FN_4O_5S \cdot 1.3 H_2O$	89–90	8.3	46.0	5.5
12h	Bu	CH ₂ COOEt	$C_{36}H_{37}FN_4O_6S$	125-126	4.4	9.0	2.1
12i	Bu	CH ₂ COOH	C ₃₄ H ₃₃ FN ₄ O ₆ S	131–132	34.0	210.0	6.2

Table III. Physical, chemical and biological data of target compounds 12 and 13.

^aAnalyses for C, H, N were correct to within $\pm 0.4\%$ of theoretical values unless otherwise stated; ^bIC₅₀ values in nM.

unsubstituted derivative **11e**. For the first time, a compound with < 10 nM binding affinities for both receptor subtypes was obtained within this series.

We continued our studies by examining the effect of the alkyl substituent at C-2 of the imidazo[4,5-c]pyridin-2-one nucleus. Previous investigations in the AT₁ selective tetrazole series showed [12] that replacement of a butyl group by a propyl or ethyl side chain slightly increased AT₁ potency. Taking this into account, we synthesized compounds 13a and 13b. The data in table III illustrate that a propyl chain in this position was the best substitution for achieving high affinities for both subtypes with a nearly mixed binding profile (13a: $AT_2/AT_1 = 2.4$). Although the 3-fluoro substituent turned out to be essential in increasing AT₂ potency, the degree of improvement depended on substituents R and R^1 (table III). Replacement of the N-5 dimethylacetamide (= R^1) in 12a with benzyl (12b), 2-oxoethyl (12c, 12e, 12f and 12g) or 3-oxopropyl (12d) substituents led to compounds which retained the low AT₂/AT₁ IC₅₀ ratios (5.5-0.5) but unfortunately showed a slight loss in binding to both receptor sites (up to almost 1 order of magnitude). The ethyl acetate analogue 12h provided no apparent advantage over the acetamide 12a in this respect. On the contrary, a possible in vivo hydrolysis to the acid 12i would lead to a compound with diminished AT_2 potency.

After optimizing the acylsulfonamide (table II) and the residues R and R^1 (table III) in the 3-fluoro series, the most balanced compounds with high potency were butyl derivative 12a and propyl derivative 13a. Both analogues still had an AT_2/AT_1 IC₅₀ ratio of 3.0 or 2.4, respectively. Therefore, we decided to focus on the acetamide function in position N-5. Variations in the length and/or bulk of the amide side chain were investigated. Several compounds with a butyl or propyl group at C-2 of the imidazo[4,5-c]pyridin-2-one nucleus (R in table IV) were prepared with different primary and secondary amines as R¹ (table IV). We were gratified to see that, compared to 12a and 13a, most of the analogues in table IV retained lower nanomolar binding affinities for both the AT₁ and AT₂ receptor, but displayed reduced IC₅₀ ratios of 1.4–0.5. When R^1 was lengthened to the *N*-benzyl derivative 120 (butyl series) or the N-isohexyl compound 13g (propyl series), there was a loss in potency for the AT_1 receptor (120 and 13g) and the AT_2 receptor (13g). This loss in potency could be due to steric (or conformational) factors. In general, propyl derivatives were slightly more potent at both receptor sites compared to their butyl analogues. This can be seen with propylamides 12m and 13e. As shown in table IV, compared to 12a, an NH₂ group (12r) was slightly diminished to AT_2 binding but had no negative effect on AT_1 potency. Propylamide 13e was one of the most active

Fable IV. Physical, a	chemical and biologica	l data of target com	pounds 12 and 13.
------------------------------	------------------------	----------------------	-------------------

				R F				
Cmpd	R	R ¹	X	Empirical formula ^a	<i>Mp</i> (° <i>C</i>)	AT ₁ ^b	AT ₂ ^b	Ratio AT_2/AT_1
12k	Bu	NHCH ₂ <i>i</i> -Pr	CH_2	C ₃₈ H ₄₂ FN ₅ O ₅ S•4.0 H ₂ O	127-128	5.8	3.3	0.57
12m	Bu	NHn-Pr	CH_2	$C_{37}H_{40}FN_5O_5S-2.3 H_2O$	125-126	3.6	3.0	0.83
12n	Bu	NHt-Bu	CH_2	$C_{38}H_{42}FN_5O_5S-2.2 H_2O$	116-117	3.9	3.0	0.77
120	Bu	NHCH ₂ Ph	CH_2	$C_{41}H_{40}FN_5O_5S \cdot 1.0 H_2O$	128-129	11.5	7.0	0.61
12p	Bu	Pip ^c	CH_2	$C_{39}H_{42}FN_5O_5S$	204-205	4.0	3.8	0.95
12q	Bu	NEt ₂	CH_2	$C_{38}H_{42}FN_5O_5S$	157-158	5.0	7.0	1.40
12r	Bu	NH ₂	CH_2	$C_{34}H_{34}FN_5O_5S-2.0 H_2O$	101-102	2.9	13.0	4.48
13c	Pr	NHn-Pn	CH_2	$C_{38}H_{41}FN_5O_5S$	131-132	8.7	8.4	0.97
13d	Pr	NHn-Bu	CH_2	$C_{37}H_{40}FN_4O_5S.0.7 H_2O$	121-122	4.6	5.6	1.22
13e	Pr	NHn-Pr	CH_2	$C_{36}H_{38}FN_5O_5S$	167–168	2.7	1.8	0.67
13f	Pr	NH(CH ₂) ₂ <i>i</i> -Pr	CH_2	$C_{38}H_{42}FN_5O_5S$	104-105	6.3	6.5	1.03
13g	Pr	NH(CH ₂) ₃ <i>i</i> -Pr	CH_2	$C_{39}H_{44}FN_5O_5S \cdot 1.5 H_2O$	107-108	14.5	18.0	1.24
13h	Pr	NHt-Bu	CH_2	$C_{37}H_{40}FN_5O_5S \cdot 1.5 H_2O$	109-110	3.7	2.1	0.57
13i	Pr	Pip ^c	CH_2	$C_{38}H_{40}FN_5O_5S$	206–207	3.6	2.6	0.72
12s	Bu	Pip ^c	0	$C_{38}H_{40}FN_5O_6S$	173–174	4.7	3.5	0.74
13k	Pr	Pip^{c}	0	$C_{37}H_{38}FN_5O_6S$	157-158	2.9	4.2	1.45

^aAnalyses for C, H, N were correct to within \pm 0.4% of theoretical values unless otherwise stated; ^bIC₅₀ values in nM; ^cpip: piperidinyl.

derivatives at both the AT₁ and AT₂ receptor with IC₅₀ values of 2.7 and 1.8 nM, respectively. Regarding tertiary amides there was no loss in AT₁ and AT₂ potency, as illustrated by the IC₅₀ values of compounds **12p**, **12q** and **13i**. Apparently there was no need for the N-H as a hydrogen-bond donor on the receptor.

Two of the tertiary amides, butyl piperidide 12p and propyl piperidide 13i, met our requirements for in vitro balance by exhibiting AT_2/AT_1 IC₅₀ ratios of 0.95 and 0.72, respectively, together with low nanomolar binding affinities for both subtypes.

Orientating studies of metabolism were carried out in vitro in order to examine the stability of the 3-fluoro acylsulfonamides 12 and 13. Incubation with microsomes of different species were carried out in buffer solution (pH 7.4), containing a NADPH regeneration system. Figure 1 shows the decrease in unchanged drug expressed as area % (HPLC). These investigations on different acylsulfonamides with rat liver microsomes showed a fast cleavage to the free sulfonamide (the free sulfonamides of compounds **9** and **10** in table I), depending on the side chain at R¹ (fig 1). Other metabolites were not detected. Cleavage to the free sulfonamide was not influenced by the side chain at C-2 (butyl or propyl) of the imidazo[4,5-c]pyridin-2-one moiety. Among the acylsulfonamides tested, the butyl and propyl piperidides **12p** and **13i** showed the highest metabolic stability. The results of some derivatives **12p**, **12r**, **13c**, **13h** and **13i** have been summarized in figure 1.

In order to raise the metabolic stability the phenylethylcarbonyl group of the sulfonylamides, **12p** and **13i** were replaced by a benzyloxycarbonyl group. This isosteric replacement of a carbon with an oxygen (X = CH₂ or O in table IV) led to sulfonylcarbamates **12s** and **13k**, respectively. Both compounds showed comparable IC₅₀ values at the AT₁ as well as the AT₂ 486



Fig 1. In vitro metabolism of selected compounds during incubation with rat liver microsomes shown as decrease in unchanged drug expressed as area % (HPLC). R = Bu, R^1 : (\Box) NHpip (12p), (\bigcirc) NH₂ (12r). R = Pr, R^1 : (\blacksquare) NH*t*-Bu (13h), (\blacklozenge) NH*n*-Pn (13c), (\bigstar) NHpip (13i).

receptor relative to acyl derivatives 12p and 13i (table IV). The in vitro stability of butyl sulfonylamide 12p and butyl sulfonylcarbamate 12s is shown in figure 2 by way of example. Incubations of 12p with rat or monkey liver microsomes showed a cleavage of 84 and 75% within 24 h, respectively. Incubation of 12s with liver microsomes of both species showed a higher stability. Only 48% of 12s was cleaved by rat liver microsomes. In addition, butyl carbamate 12s was nearly completely stable during incubation with monkey liver microsomes (fig 2).

A model of the AT₁ receptor–ligand interactions for 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-c]pyridine-based AT₁ selective ang II antagonists has been discussed [12]. Possible roles have been proposed for substituents at C-2, N-5 and at the biphenyl moiety (cf, formula in table III), briefly, for interactions with the AT_1 receptor: (i) hydrophobic associations between a lipophilic pocket and an aliphatic chain at C-2; (ii) an ionic interaction between a cationic group on the receptor and the acidic substituent on the biphenyl chain; and (iii) a hydrogen bond between a proton donor on the receptor and an oxygen as a proton acceptor at N-5 (eg, the acetamides). The AT₂ receptor was quite sensitive to changes in the substituent of the acylsulfonamide. There was a slight preference for phenylethyl or benzyloxy over other acylsulfonamides. The acylsulfonamide could be involved in hydrogen-bonding with the AT₂ receptor, and the lipophilic tail (phenylethyl or benzyloxy) was needed to reach a hydrophobic pocket on the receptor. A propyl chain at C-2 was most effective in establishing an important hydrophobic contact to this receptor. More importantly, the substantial increase in $A\bar{T}_2$ binding affinity attained by the 3-fluoro substituent on the biphenyl moiety strongly suggested that the fluoro



Fig 2. Metabolic stability of butyl sulfonylamide 12p during incubation with rat (\bigcirc) or monkey (\bigcirc) and butyl carbamate 12s with rat (\blacksquare) or monkey (\Box) liver microsomes.

atom was involved in a discrete interaction with the AT_2 receptor. The requirement of a fluorine at that particular position implies that this atom is directly involved in binding, perhaps by interacting with a hydrophobic site. At the N-5 position, binding to the AT_2 receptor was sensitive to changes in the size and shape of the amide substituent (eg, piperidine). Again, the carbonyl function of the acetamides was involved in hydrogen-bonding whereas the piperidine was important in making a hydrophobic interaction with the AT_2 receptor.

Quan et al [21] had shown that the ratio of the half maximal inhibition constants (IC₅₀ values) for the AT₁ and AT₂ receptor binding affinities critically depend upon the radioligand used. They found that compounds which possessed a balanced AT_2/AT_1 ratio when using [125I] ang II as the ligand, displayed a heavily deranged AT_2/AT_1 ratio when using [¹²⁵I] [Sar¹, Ile⁸] ang II as the radioligand instead. This derangement was largely due to an improvement in the apparent AT_1 receptor affinity and a concomitantly occurring decrease in the AT_2 receptor affinity. While Quan et al were able to overcome this imbalance in the AT_1/AT_2 receptor binding affinities by appropriate structural modifications of their compounds, the possibility of an only apparent balance in the AT₁/AT₂ receptor affinity ratio of our compounds caused some concern. At least all our binding data had been obtained using [125I] ang II as the radioligand. We therefore carried out binding experiments with [125I] [Sar¹, Ile⁸] ang II as the radioligand using selected compounds. The results obtained with 12k, 12s and 13f are summarized in table V. While we observed a slight, but not unexpected, decrease in the IC_{50} values of our test compounds when using [125I] [Sar¹, Ile⁸] ang II as the ligand, the IC_{50} ratios of the AT_1/AT_2

Cmpd	[¹²⁵ I] ang II		Ratio	[¹²⁵]] [Sar ¹ , Ile ⁸] ang II		Ratio
-	AT_{I}^{a}	AT_2^{a}	AT_2/AT_1	AT_{I}^{a}	AT_2^{a}	AT_2/AT
12k	5.8	3.3	0.6	10	13.5	1.4
12s	4.7	3.5	0.7	6.0	20	3.3
13f	6.3	6.5	1.0	7.5	13.5	1.8

Table V. Comparison of IC_{50} values of selected AT_1/AT_2 receptor antagonists with regard to the displacement of $[^{125}I]$ ang II and $[^{125}I]$ [Sar¹, Ile⁸] ang II.

^aIC₅₀ values in nM.

receptors were only minimally affected, indicating that our compounds were already optimized with regard to the AT_1 as well as the AT_2 receptor binding. Since in addition under in vivo conditions the natural ligand will be ang II, we decided not to elaborate further on improving our already well balanced ang II receptor antagonists.

The in vitro AT_1 antagonism of all tested acetamides in tables III and IV was in the nano- or subnanomolar range. Data of piperidides **12p**, **12s**, **13i** and **13k** are shown in table VI together with those of the reference compounds **1–4**. These data indicate that both sulfonylcarbamates **12s** and **13k** were superior to losartan **1**, L-159,689 **4** and equipotent to EMD 66684 **2** concerning their functional AT_1 potency in vitro.

Of all investigated sulfonamides, piperidide 12s met best our stringent target for balanced in vitro binding affinity together with high AT₁ antagonism and in vitro metabolic stability. As a potent representative of this class of compounds, 12s was selected as

its potassium salt EMD 90423 for in vivo evaluation as an antihypertensive drug.

As shown in table VII, EMD 90423 and losartan were given orally at a dose of 3 mg/kg to conscious, sodium-depleted cynomolgus monkeys. Heart rate (HR), arterial blood pressure (AP) and plasma renin activity (PRA) were measured 1 and 3 h after administration. EMD 90423 produced a maximum hypotensive response of 26.3% in systolic, 27.5% in diastolic and 32.6% in mean arterial blood pressure accompanied by a maximum rise of 73.3% in plasma renin activity. However, the maximum blood pressure lowering effect of losartan amounted only to 11.7% in systolic, 9.5% in diastolic and 12.4% in mean arterial blood pressure, and the maximum rise of plasma renin activity was 52.4%. Heart rate was changed only to a small extent in both compounds. The observed fall of blood pressure of our compound lasted for more than 8 h (data not shown in table VII), which demonstrated the high efficacy of EMD 90423 after oral administration.

Table VI. In vitro binding (AT_1, AT_2) and antagonism (AT_1) of selected acylsulfonamides 12, 13 and reference compounds 1-4.



Cmpd	R	X	Binding AT_l^{a}	Binding AT_2^a	Ratio AT_2/AT_1	Antagonism AT ₁ ^a
12p	Bu	CH ₂	4.0	3.8	0.95	0.30
13i	Pr	CH_2	3.6	2.6	0.57	0.90
12s	Bu	0	4.7	3.5	0.74	0.18
13k	Pr	Ō	2.9	4.2	1.45	0.20
1 ^b	_	_	8.2	> 10 000	> 1220	3.00
2 ^c	-	_	0.7	> 10 000	>14 286	0.20
3 ^d	-	_	> 10 000	30.0	< 0.003	
4 ^e	-		2.3	1.3	0.57	0.80

^aIC₅₀ values in nM; ^blosartan; ^cEMD 66684; ^dPD 123,177; ^eL-159,689.

Parameters	EMD 90423	Δ % baseline	Losartan	Δ % baseline
HR (bpm)	·		· · · · · · · · · · · · · · · · · · ·	
Baseline	181.1 ± 19.6	_	168.2 ± 13.4	_
1 h	168.2 ± 24.7	- 7.1	154.6 ± 14.7	- 8.1
3 h	169.7 ± 25.7	- 6.3	168.5 ± 11.1	+ 0.2
AP syst (mmHg)				
Baseline	98.3 ± 10.7	_	93.5 ± 4.9	
1 h	80.5 ± 7.4	- 18.1	82.6 ± 10.2	- 11.7
3 h	72.4 ± 5.6	- 26.3	86.3 ± 6.4	- 7.7
AP diast (mmHg)				
Baseline	61.4 ± 6.6	_	55.5 ± 4.3	_
1 h	45.1 ± 4.2	- 26.5	50.2 ± 8.1	- 9.5
3 h	44.5 ± 3.1	- 27.5	54.2 ± 7.3	- 2.3
AP mean (mmHg)				
Baseline	78.3 ± 8.6	_	70.3 ± 5.0	_
1 h	55.5 ± 3.1	- 29.1	61.6 ± 9.4	- 12.4
3 h	52.8 ± 3.4	- 32.6	66.6 ± 7.8	- 5.3
PRA (ng ang I/mL/h)				
Baseline	44.2 ± 19.3	_	39.5 ± 10.2	-
1 h	76.6 ± 24.8	+ 73.3	60.2 ± 16.8	+ 52.4
3 h	75.1(n=2)	+ 69.9	58.8 ± 14.0	+48.9

Table VII. Effects of a 3 mg/kg oral dose of EMD 90423 (potassium salt of compound **12s**) and losartan in salt-depleted cynomolgus monkeys 1 and 3 h after administration. Results are shown as means \pm SEM of 3–4 animals.

Bpm: beats per minute; h: hour; AP syst: systolic arterial blood pressure; AP diast: diastolic arterial blood pressure; AP mean: mean arterial blood pressure; PRA: plasma renin activity; ang I: angiotensin I.

Conclusions

This paper describes a novel series of potent nonpeptide ang II AT₁ antagonists with balanced affinity for the AT_1 and AT_2 receptor subtypes derived from substitution of a 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-c]pyridine nucleus. Compounds with a propyl or a butyl group at C-2, different acetamides at N-5, a 3-fluoro and a 2'-carboxamidosulfonyl substituent at the biphenylmethyl moiety exhibited nanomolar affinities for both the AT_1 and AT_2 receptor. Replacement of the phenylethylcarbonyl by a benzyloxycarbonyl group at the sulfonamide position gave rise to an improvement in metabolic stability in vitro. With acetylpiperidide 12s, one of the most potent AT_1/AT_2 balanced affinity antagonists actually known related to in vitro properties was observed. After oral administration to cynomolgus monkeys, EMD 90423 demonstrated good efficacy and a long duration of action as an antihypertensive drug. These results make this ang II antagonist a promising candidate for the treatment of hypertension and congestive heart failure if AT₂ functions are proven to be physiologically significant.

Experimental protocols

Chemistry

Melting points were determined with a HWS Labortechnik SGV 500 Plus melting point apparatus and are uncorrected. IR, NMR, and mass spectra are in agreement with the structures cited and were recorded on a Bruker 85 IFS 48 IR spectrophotometer, a Bruker AC 200, WM 250 or AM 500 (TMS as internal standard), and a Fisons (formerly Vacuum Generator) VG 70-70E (electron-impact: ei) or 70-250SE (fast atom bombardement: fab) at 70 eV, respectively. Microanalyses were obtained with a Perkin-Elmer 240B CHN analyzer. Thinlayer chromatography (TLC) was carried out on precoated silica gel 60 F_{254} plates with a layer thickness of 0.25 mm from Merck KGaA (Darmstadt, Germany). Visualization was per-formed with UV and I_2 . Yields were not optimized. The preparative chromatography was performed on Merck KGaA silica gel 60 (230–400 mesh) and all solvents were of Merck extra-pure grade. NADP, G6P, G6PDH, Na_2 –EDTA, MgCl₂·6 H₂O, K₂HPO₄ and NaH₂PO₄ were purchased from Merck KGaA (Darmstadt, Germany), the protein-assay reagent came from Pierce (Rockford, USA).

General procedure for the preparation of 3-[[2'-tert-butylaminosulfonyl-4-biphenylyl]methyl]-4,5-dihydro-3H-imidazo[4,5-c]pyridin-4-ones **6**

Compounds 6 (scheme 2) were synthesized by the representative procedure illustrated for 6 [R = Bu, $R_1 = F$]. 2-Butyl-3-[[3-fluoro-(2'-tert-butylaminosulfonyl)-4-biphenylyl]methyl]-4,5-dihydro-3H-imidazo[4,5-c]pyridin-4-one 6. For the preparation of this compound $[R = Bu, R_1 = F]$, the solution of 2-butyl-4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine 5a (30.0 g, 157.0 mmol) in dimethylformamide (500 mL) was treated with finely-ground potassium carbonate (21.7 157.0 mmol) and 4'-(bromomethyl)-3'-fluoro-N-tert-butyl-2 biphenylsulfonamide (62.8 g, 157.0 mmol). The reaction mixture was stirred at ambient temperature overnight. It was diluted with water (800 mL) and extracted with ethyl acetate (3 x 300 mL). After drying over anhydrous sodium sulfate, the solvent was evaporated to yield a yellow oil which was purified by flash chromatography on silica gel with ethyl acetate as eluent to provide 33.3 g (42%) of **6** [R = Bu, $R_1 = F$] as white crystals and 5.4 g (5.4%) of the bisadduct 7 [R = Bu, $R_1 = F$]. **6** [R = Bu, $R_1 = F$]: mp = 261–262 °C; ¹H-NMR (DMSO- d_0) δ ppm: 11.30 (sbr, 1H), 8.07 (dd, J = 1.1 Hz, J = 8.0 Hz, 1H), 7.65 (td, J = 1.2 Hz, J = 7.2 Hz, 1H), 7.61 (td, J = 1.5 Hz, J =7.6 Hz, 1H), 7.32 (td, J = 1.2 Hz, J = 7.5 Hz, 1H), 7.16 (dd, J =1.6 Hz, J = 8.0 Hz, 1H), 7.14 (dd, J = 1.6 Hz, J = 6.9 Hz, 1H), 6.88 (t, J = 8.0 Hz, 1H), 6.84 (s, 1H), 6.59 (d, J = 7.1 Hz, 1H), 5.89 (s, 2H), 2.73 (t, J = 7.4 Hz, 2H), 1.72–1.66 (m, 2H), 1.40–1.32 (m, 2H), 1.01 (s, 9H), 0.89 (t, J = 7.4 Hz, 3H). Anal (C, H, N) $C_{27}H_{31}FN_4O_3S$. 7 [R = Bu, R₁ = F]: mp = 106-107 °C; ¹H-NMR (DMSO- d_6) δ ppm: 8.07 (d, J = 7.7 Hz, 1H), 7.66–7.55 (m, 5H), 7.35–7.26 (m, 4H), 7.20–7.14 (m, 3H), 6.92-6.85 (m, 3H), 6.74 (d, J = 7.2 Hz, 1H), 5.91 (s, 2H), 5.35 (s, 2H), 2.75 (t, J = 7.4 Hz, 2H), 1.74–1.66 (m, 2H), 1.41–1.34 (m, 2H), 1.04 (s, 9H), 1.00 (s, 9H), 0.90 (t, J = 7.4 Hz, 3H). Anal (C, H, N) C44H49F2N5O5S2.

General procedure for the preparation of 3-[[2'-tert-butylaminosulfonyl-4-biphenylyl]methyl]-4,5-dihydro-3H-imidazo[4,5-c]pyridin-4-ones 8, 9 and 10

Most compounds **8**, **9** and **10** (table I) were synthesized by the representative procedure illustrated for **90**.

2-Butyl-3-[[3-fluoro-(2'-tert-butylaminosulfonyl)-4-biphenylyl]methyl]-4,5-dihydro-5-[(2-oxo-2-piperidino)ethyl]-3Himidazo[4,5-c]pyridin-4-one 90. Under a nitrogen atmosphere, 6 [R = Bu, $R_1 = F$] (1.15 g, 2.32 mmol) was dissolved in dry dimethylformamide (15 mL). At ambient temperature, potassium tert-butoxide (0.29 g, 2.55 mmol) was added to the solution. After the resulting mixture had been stirred at the same temperature for 15 min, 1-chloroacetylpiperidine (0.41 g, 2.55 mmol) was added at once. The reaction mixture was stirred for 18 h at ambient temperature and concentrated in vacuo to an oil, which was partitioned between water (50 mL) and ethyl acetate (50 mL). The organic extract was dried on Na₂SO₄, concentrated in vacuo, and chromatographed on silica gel with 50% ethyl acetate in hexane as eluent. Recrystallization from 50% ethyl acetate in diethylether provided 1.28 g (89%) of **90** as white crystals, mp = 145-146 °C. ¹H-NMR $(DMSO-d_6) \delta$ ppm: 8.03 (dd, J = 1.0 Hz, J = 8.0 Hz, 1H), 7.62 (td, J = 1.1 Hz, J = 7.4 Hz, 1H), 7.56 (td, J = 1.0 Hz, J = 7.4 Hz, 1H), 7.30 (d, J = 7.3 Hz, 1H), 7.27 (dd, J = 1.5 Hz, J = 8.0 Hz, 1H), 7.15 (dd, J = 1.6 Hz, J = 8.0 Hz, 1H), 6.80 (s, 1H), 6.77 (t, J = 7.9 Hz, 1H), 6.60 (d, J = 7.3 Hz, 1H), 5.84 (s, 2H), 4.86 (s, 2H), 3.49–3.40 (m, 4H), 2.70 (t, J = 7.4 Hz, 2H), 1.77-1.69 (m, 2H), 1.64-1.54 (m, 4H), 1.47-1.43 (m, 2H), 0.97 (s, 9H), 0.92 (t, J = 7.4 Hz, 3H). Anal (C, H, N) $C_{34}H_{42}FN_5O_4S$

General procedure for the preparation of 3-[[2'-carboxamidosulfonyl-4-biphenyly]methyl]-4,5-dihydro-3H-imidazo[4,5-c]pyridin-4-ones 11, 12 and 13

Most compounds **11**, **12** and **13** (tables II–IV) were synthesized by the representative procedure illustrated for **12p**.

2-Butyl-3-[[3-fluoro-2'-(3-phenylethylcarboxamidosulfonyl)-4biphenylyl]methyl]-4,5-dihydro-5-{(2-oxo-2-piperidino)ethyl}-3H-imidazo[4,5-c]pyridin-4-one **12p**. A solution of **90** (1.28 g, 2.06 mmol) in trifluoroacetic acid (TFA, 10 mL) was stirred overnight at ambient temperature. The excess TFA and volatiles were removed in vacuo to give the crude sulfamoyl intermediate. To a solution of the crude product in pyridine (20 mL) under a nitrogen atmosphere was added at ambient temperature 4-dimethylaminopyridine (0.50 g, 4.13 mmol). After stirring at ambient temperature for 0.5 h the mixture was cooled to 5 °C, 3-phenylpropionyl chloride (0.61 mL, 4.13 mmol) was added dropwise and the resulting mixture was stirred at ambient temperature for 48 h. The reaction mixture was quenched by addition of water (200 mL) and extracted with ethyl acetate (3 x 100 mL). The organic extract was dried on Na₂SO₄, concentrated in vacuo, and chromatographed on silica gel with ethyl acetate. Recrystallization from 50% ethyl acetate in diethylether provided 1.21 g (84%) of **12p** as white crystals, mp = 204–205 °C. ¹H-NMR (DMSO– d_6) δ ppm: 11.68 (s, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.3 Hz, 1H), 7.33 (d, J =7.5 Hz, 1H), 7.27–7.16 (m, 4H), 7.11 (d, J = 7.4 Hz, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.76 (t, J = 7.9 Hz, 1H), 6.66 (d, J = 7.9 Hz, 1H), 7.3 Hz, 1H), 5.88 (s, 2H), 4.90 (s, 2H), 3.52-3.44 (m, 4H), 2.71–2.65 (m, 4H), 2.55 (q, J = 7.4 Hz, 2H), 1.68–1.50 (m, 6H), 1.49–1.42 (m, 2H), 1.34–1.24 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). Anal (C, H, N) C₃₉H₄₂FN₅O₅S.

Alternative procedure for the preparation of 3-[[2'tert-butylaminosulfonyl-4-biphenylyl]methyl]-4,5-dihydro-3H-imidazo[4,5-c]pyridin-4-one intermediates 9 and 10

Some compounds **10** (scheme 3, table 1) were synthesized by the representative procedure illustrated for **10i**.

3-(4-Bromo-2-fluorobenzyl)-4,5-dihydro-4-oxo-2-propyl-3H-imidazo[4,5-c]pyridine 15. To a solution of N-(4-amino-2-chloro-3-pyridyl)butyramide 12 (65.3 g, 305.0 mmol) in1-methyl-2-pyrrolidinone (NMP, 300 mL) was added a solution of potassium tert-butoxide (37.7 g, 336.0 mmol) in NMP (100 mL) under a nitrogen atmosphere, and the reaction mixture was stirred for 0.5 h. A solution of 4-bromo-2-fluorobenzylbromide (90.0 g, 336.0 mmol) in NMP (200 mL) was added dropwise, and the reaction mixture was stirred for 4 h. The reaction mixture of the intermediates 13 and 14 (which can be identified by usual workup) was treated with hydrochloric acid (32%, 600 mL) and heated at 105 °C for 18 h. The solution was cooled to ambient temperature, the resultant precipitate was filtered, washed with water, and dried in vacuo. Recrystallization of the residue from ethyl acetate yielded 80.3 g (72%) of 15 as white crystals, mp = 178-179 °C. ¹H-NMR (DMSO- d_6) δ ppm: 11.21 (sbr, 1H). 7.59 (dd, J = 2.0 Hz, J = 9.9 Hz, 1H), 7.37 (dd, J = 2.1 Hz, J = 8.2 Hz, 1H), 7.07 (d, J = 6.9 Hz, 1H), 6.74 (t, J = 8.2 Hz, 1H), 6.53 (d, J =6.9 Hz, 1H), 5.73 (s, 2H), 2.65 (t, J = 7.3 Hz, 2H), 1.76–1.56 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H). Anal (C, H, N) C₁₆H₁₅BrFN₃O.

3-(4-Bromo-2-fluorobenzyl)-4.5-dihydro-5-(2-oxo-2-(1-piperidyl)ethyl)-2-propyl-3H-imidazo[4,5-c]pyridin-4-one **16**. Under a nitrogen atmosphere a mixture of **15** (5.0 g, 12.5 mmol), potassium *tert*-butoxide (1.5 g, 13.5 mmol), and DMF (50.0 mL) was stirred at 5 °C for 0.5 h. Subsequently, 1-chloracetylpiperidine (1.4 g, 13.5 mmol) was added dropwise and the reaction mixture was stirred at ambient temperature for 3.0 h. The reaction mixture was concentrated in vacuo to an oil which was partitioned between water (200 mL) and ethyl acetate (200 mL). The organic extract was dried on Na₂SO₄, concentrated in vacuo, and chromatographed on silica gel with 50% ethyl acetate in hexane as eluent. Recrystallization from 50% ethyl acetate in diethylether provided 5.1 g (83 %) of **16** as white crystals, mp = 156–157 °C. ¹H-NMR (DMSO–*d*₆) δ ppm: 7.59 (dd, J = 1.9 Hz, J = 9.9 Hz, 1H), 7.34 (dd, J = 2.3 Hz, J = 8.3 Hz, 1H), 7.28 (d, J = 7.3 Hz, 1H), 6.67 (t, J = 8.3 Hz, 1H), 6.58 (d, J = 7.2 Hz, 1H), 5.72 (s, 2H), 4.83 (s, 2H), 3.49–3.36 (m, 4H), 2.68 (t, J = 7.3 Hz, 2H), 1.79–1.59 (m, 2H), 1.59–1.36 (m, 4H), 0.90 (t, J = 7.3 Hz, 3H). Anal (C, H, N) C₂₃H₂₆BrFN₄O₂.

3-[[3-Fluoro-(2'-tert-butylaminosulfonyl)-4-biphenylyl]methyl]-4,5-dihydro-5-(2-oxo-2-(1-piperidyl)ethyl)-2-propyl-3H-imidazo[4,5-c]pyridin-4-one **10i**. A solution of **16** (1.0 g, 2.04 mmol) in dimethoxyethane (50.0 mL) was treated with 2 N sodium carbonate (10.0 mL), [2-(*N-tert*-butylsulfamoyl)-phenyl]boronic acid (2.63 g, 10.2 mmol) and [1,1'-bis-(diphenylphosphino)ferrocene]dichloropalladium (II) (0.2 g, 0.17 mmol) successively. The mixture was stirred at 84 °C for 1.5 h, cooled to room temperature, quenched with water (150 mL) and extracted with ethyl acetate (3 x 100 mL). The organic extract was dried on Na₂SO₄, concentrated in vacuo, and chromatographed on silica gel with ethyl acetate. Recrystallization from 50% ethyl acetate in *n*-heptane provided 1.16 g (94%) of 10i as light yellow crystals, mp = 154-155 °C. ¹H-NMR (DMSO- d_6) δ ppm: 8.03 (dd, J = 1.5 Hz, J = 7.3 Hz, 1H), 7.62 (td, J = 1.5 Hz, J = 7.4 Hz, 1H), 7.57 (td, J = 1.6 Hz, J = 7.7 Hz, 1H), 7.31 (d, J = 7.3 Hz, 1H), 7.28 (dd, J = 1.6 Hz, J = 7.7 Hz, 1H), 7.11 (dd, J = 1.6 Hz, J = 7.9 Hz, 1H), 6.82 (s, 1H), 6.77 (t, J = 7.9 Hz, 1H), 6.60 (d, J = 7.3 Hz, 1H), 5.85 (s, 2H), 4.87 (s, 2H), 3.49-3.40 (m, 4H), 2.69 (t, J = 7.4 Hz, 2H), 1.77-1.69 (m, 2H), 1.64-1.53 (m, 4H), 1.48-1.42 (m, 2H), 1.00 (s, 9H), 0.92 (t, J = 7.4 Hz, 3H). Anal (C, H, N) C33H40FN5O4S.

3-[{3-Fluoro-2'(3-phenylethylcarboxamidosulfonyl)-4-biphenylyl]methyl]-4.5-dihydro-5-[(2-oxo-2-piperidino)ethyl]-2-propyl-3H-imidazo[4,5-c]pyridin-4-one **13i**. This compound was prepared from **10i** (1.0 g, 1.61 mmol) according to the synthesis of compound **12p** and provided 0.91 g (81%) of **13i** as white crystals, mp = 206–207 °C. ¹H-NMR (DMSO–d₆) & ppm: 11.64 (s, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.70 (t, J =7.4 Hz, 1H), 7.62 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 7.3 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.23–7.12 (m, 4H), 7.07 (d, J = 7.3 Hz, 2H), 6.87 (d, J = 7.9 Hz, 1H), 6.61 (t, J = 7.9 Hz, 1H), 6.61 (d, J = 7.2 Hz, 1H), 5.84 (s, 2H), 4.86 (s, 2H), 3.48–3.40 (m, 4H), 2.66–2.61 (m, 4H), 2.26 (t, J = 7.5 Hz, 2H), 1.73–1.64 (m, 2H), 1.63–1.53 (m, 4H), 1.47–1.41 (m, 2H), 0.87 (t, J =7.4 Hz, 3H). Anal (C, H, N) C₃₈H₄₀FN₅O₆S.

Biology

Angiotensin II receptor binding assay

Wistar rats were killed by decapitation and the adrenal glands removed. By applying a slight positive pressure onto the glands the capsular layer was separated from the medulla. All subsequent steps were carried out at 4 °C. The tissues were collected separately in 200 mM sucrose, 1.0 mM EDTA, 10 mM Tris/HCl, pH 7.2. The glomerulosa cell layers were homogenized using a Polytron PT 10/35 followed by three strokes in a glass/teflon homogenizer. The homogenate was centrifuged for 10 min at 3000 g. The supernatant was filtered through gauze; the filtrate was centrifuged for 13 min at 12 000 g. The membrane vesicles contained in the supernatant were sedimented by centrifugation for 60 min at 102 000 g. The supernatant was discarded; the pellet was resuspended in 0.25% BSA, 5 mM MgCl₂, 50 mM Tris/HCl, pH 7.2, and was stored frozen in 1-2-mL aliquots in liquid N₂. Plasma membrane vesicles from the medullary portion were prepared in an identical fashion.

Before carrying out the binding assays, the frozen stored membrane solutions were thawed and appropriately diluted in 0.25% BSA. 5 mM MgCl₂, 50 mM Tris/HCl, pH 7.2. The medulla plasma membrane solution was incubated in the presence of 5 mM DTT for 20 min at 30 °C to inactivate the residual AT₁-receptors in this preparation.

The binding assay was carried out in a total of 500 μ L; 400 μ L of the membrane suspension (appropriately diluted with 0.25 or 0.0067% BSA (to achieve 0.25 or 0.01% BSA in the membrane suspension), 5 mM MgCl₂, 50 mM Tris/HCl, pH 7.2), 50 μ L of [¹²⁵I]-ang II (conc between 0.06 and 0.12 nM), and 50 μ L of a 10% DMSO solution containing various amounts of unlabelled ang II or competitors. Each concentration was determined in triplicate. The incubation was carried out for 60 min at room temperature. The incubation was terminated by rapidly filtering the incubation volume through Whatman GF/C filters, which were rinsed immediately with 2 x 4 mL ice-cold 0.9% NaCl solution. The radioactivity trapped on the filter were counted in a g-counter (Packard, Cobra 5010). Non specific binding was determined in the presence of 1 μ M unlabelled ang II. The effect of the competitors were determined by estimating the concentration at which they displayed the bound [¹²⁵I]-ang II half maximally.

Antagonism of angiotensin II-contracted rabbit aortic rings

New Zealand white rabbits were stunned by a blow to the head and exsanguinated. The aorta was excised and placed in an oxygenated O_2/CO_2 (95%:5%) physiological salt solution consisting of (mM) NaCl, 118.1; KCl, 4.7; MgSO₄, 1.2; KH₂PO₄, 1.2; NaHCO₃, 25; and glucose, 11.1.

The aorta was dissected free from fat and connective tissue and cut into rings of approximately 2 mm. The rings were mounted into 50-mL organ baths and were allowed to equilibrate for 60 to 90 min under a resting tension of 2 g. After equilibration, a cumulative concentration-contractile response curve for ang II was obtained. After a washout period, the rings were contracted with ang II at a concentration which induced 50% of the maximal response (3-8 nM). After a stable value was obtained, the preparations were washed three times and the tension was allowed to return to the baseline. This procedure was repeated every 40 min for a total of three or four cycles. The level of the concentration observed during the last cycle was used as the control (predrug) value. Subsequent contractions were obtained in the presence of increasing concentrations of the test compound, which was added 15 min prior to the agonist. One out of four vessel rings was exposed to the solvent without the test compound and served as time and solvent control in each experiment. The reduction in contractile force in the presence of the test compound was expressed as a percentage of the predrug value. Data were expressed as mean values. IC₅₀ values (concentrations required to inhibit predrug responses by 50%) were determined graphically.

Preparation of liver microsomes

Male Wistar rats were used to prepare liver microsomes. The rats were killed by decapitation and the livers homogenized with 2 vol phosphate buffer, 0.1 M, pH 7.4. Microsomes were prepared according to the method of Kremers et al [29]. The final microsomal pellets were resuspended in phosphate buffer and stored at -80 °C. The protein concentration of the microsomal preparation was determined by the method of Bradford [30]. Monkey livers were obtained from Corning Hazeleton

GmbH, Münster, Germany. Monkey liver microsomes were prepared by the same way as described above for rat liver microsomes.

Incubation procedures

The metabolism of AT_1/AT_2 antagonists was measured in standard assay mixtures that contained the following in a final vol of 10 mL: 0.1 M phosphate buffer (pH 7.4), 15 mg microsomal proteins, 1.77 mM G6P, 0.42 mM NADP, 1 mM MgCl₂•6H₂O and 0.25 mg drug, solved in 0.25 mL ethanol. After 1 min preincubation at 37 °C the reaction was initiated by the addition of 0.23 U/mL G6PDH. At the appropriate times, samples of 1 mL were taken, then the reaction was stopped by the addition of 3 mL ethanol. Upon cooling on ice and subsequent centrifugation (2.5 min, 8000 g) to pellet the denaturated proteins, the supernatant was evaporated to dryness and resolved in acetonitrile (40%), sterile-filtered (0.45 µm) and analyzed by HPLC.

Chromatographic analysis

For the HPLC a Merck-Hitachi pump 655A-12 was employed with a L 5000 LC contoller, 655-A-40 autosampler, L 4200 UV/visible light detector, a D-2500 chromato-integrator. Separation of drug and metabolites was performed on a Li-Chrosorb RP 8, 7- μ m, 250-column with an acetonitrile/water gradient from 40/60 to 25/75 (+ 0.015% TFA) as elution solvent at a flow rate of 1 mL/min, and the eluate was monitored at 230 nm. Products were identified by EI–MS.

In vivo activity

Female cynomolgus monkeys (Macaca fascicularis) weighing 3-8 kg were used. The animals were housed under constant temperature and lighting conditions and provided with food consisting of a commercial pellet diet for monkeys (Sniff p no 2/81013), cereal mixture, barley germ, fruit and vegetables. The animals were treated daily with furosemide, 4 mg/kg im, beginning on the fourth day before an experiment. On the day of the experiment the animals were treated with the final dose of furosemide. Ten min before each measurement the animals were treated with ketamine (Ketavet[®], Parke Davis), 0.4 mg/kg im, for sedation. About 1.5 h after the last furosemide treatment, arterial blood pressure (AP) and heart rate (HR) were measured by the cuff method (Dinamap[®], Vital-Daten-Monitor 1846, Critikon). In detail, a pneumatic cuff (Critikon Disposa-Cuff®, no 2500, range 8-13 cm) was positioned on the upper arm of the monkeys and AP and HR were measured every minute and were allowed to stabilize before drug administration. Following this, test substances were applied orally and AP and HR were measured after 0, 1 and 3 h. Blood samples for the measurement of PRA were collected before and after administration of the compounds as indicated. The blood samples were taken by direct puncture of the saphenous vein.

Acknowledgments

We wish to extend our thanks to V Eiermann and KGR Pachler for the measurement and interpretation of the NMR spectra. We would also like to thank R Emmerich, M Germann, R Licht, A Liebig-Weber, K Rauschenbach-Ruess, B Schneider, L Schulze and R Zissel for their skillful experimental work. We are grateful to U Zühlke, Corning Hazleton, for his support in supplying us with the monkey liver.

References

- 1 Peach MJ (1977) Physiol Rev 57, 313-370
- 2 Greenlee WJ, Siegl PKS (1992) angiotensin/renin modulators. In: Annual Reports. Medicinal Chemistry (Bristol JA, ed) Academic Press, Amsterdam, 59–68
- 3 Israili ZH, Hall WD (1992) Ann Intern Med 117, 234-242
- 4 Chiu AT, Herblin WF, McCall DE et al (1989) Biochem Biophys Res Commun 165, 196–203
- 5 Wong PC, Hart SD, Zaspel AM et al (1990) J Pharmacol Exp Ther 255, 584–592
- 6 Sasaki K, Yamano Y, Bardhan S et al (1991) Nature 351, 230-233
- 7 Timmermans PBMWM, Wong PC, Chiu AT et al (1993) *Pharmacol Rev* 45, 205–251
- 8 Chakravarty PK (1995) Exp Opin Ther Pat 5, 431-458
- 9 Osswald M, Mederski WWKR, Schwarz M, Beier N, Lues I. Minck KO (1994) *Bioorg Med Chem Lett* 4, 683–688
- 10 Koppe T, Mederski WWKR, Osswald M, Schwarz M (1995) Tetrahedron Lett 36, 377–380
- 11 Dorsch D, Mederski WWKR, Beier N, Lues I, Minck KO, Schelling P (1994) Bioorg Med Chem Lett 4, 1297–1302
- 12 Mederski WWKR, Dorsch D, Bokel HH, Beier N, Lues I, Schelling P (1994) J Med Chem 37, 1632–1645
- 13 Beier N, Labitzke E, Mederski WWKR, Radunz HE, Rauschenbach-Ruess K, Schneider B (1994) *Heterocycles* 39, 117–131
- 14 Dorsch D, Mederski WWKR, Osswald M, Beier N, Schelling P (1995) Bioorg Med Chem Lett 5, 2071–2076
- 15 Blankley CJ, Hodges JC, Klutchko SR et al (1991) J Med Chem 34, 3248-3260
- 16 Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) J Biol Chem 268, 24539–24542
- 17 Kambayashi Y, Bardhan S, Takahashi K et al (1993) J Biol Chem 268, 24543-24546
- 18 Christen Y, Waeber B, Nussberger J et al (1991) Circulation 83, 1333-1342
- 19 de Laszlo SE, Quagliato CS, Greenlee WJ et al (1993) J Med Chem 36, 3207-3210
- 20 Chang LL, Ashton WT, Flanagan KL et al (1994) J Med Chem 37, 4464-4478
- 21 Quan ML, Chiu AT, Ellis CD, Wong PC, Wexler RR, Timmermans PBMWM (1995) J Med Chem 38, 2938–2945
- 22 Walsh TF, Fitch KJ, Chang RSL et al (1995) Bioorg Med Chem Lett 5, 1151– 1154
- 23 Deprez P, Guillaume J, Corbier A, Vevert JP, Fortin M, Heckmann B (1995) Bioorg Med Chem Lett 5, 2617–2622
- 24 Chang LL, Ashton WT, Flanagan KL et al (1995) J Med Chem 38, 3741-3758
- 25 Mederski WWKR, Dorsch D, Osswald M et al (1995) *Bioorg Med Chem Lett* 5, 2665–2670
- 26 Naylor EM, Chakravarty PK, Costello CA et al (1994) Bioorg Med Chem Lett 4, 69-74
- 27 Hayashi T, Konishi M, Kobori Y, Kumada M, Higuchi T, Hirotsu K (1984) J Am Chem Soc 106, 158–163
- 28 Quan ML, Olson RE, Carini DJ et al (1994) Bioorg Med Chem Lett 4, 2011– 2016
- 29 Bradford MM (1976) Anal Biochem 72, 248-254
- 30 Kremers P, Beaune P, Cresteil T et al (1981) Eur J Biochem 118, 599-606